Back

Effects of atrial fibrillation ablation in patients with stroke risk factors: the CABANA Trial.

28 August 2018 (14:30 - 14:48)
Organised by:
Congress Presentation Part of: Is atrial fibrillation ablation a mature treatment to reduce morbi-mortality? Outcomes and Complications ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor Douglas L Packer

Intermountain Cardiovascular Research Institute, Salt Lake City (United States of America)

3 More presentations in this session

Presentation thumbnail
Effects of atrial fibrillation ablation in patients with lV dysfunction: the CASTE-AF trial.
Professor J. Brachmann (Coburg, DE)
Slides Video
Presentation thumbnail
Critical appraisal of the CABANA and CASTLE-AF trials.
Professor I. Van Gelder (Groningen, NL)
Slides Video
Presentation thumbnail
Will the technical improvements in atrial fibrillation ablation further improve the success of atrial fibrillation ablation.
Professor G. Hindricks (Berlin, DE)

Access the full session

Session thumbnail
Is atrial fibrillation ablation a mature treatment to reduce morbi-mortality?

The Event

Event poster

ESC Congress 2018

28 August 2018 14:30 CET
You may be interested in
thumbnail
Congress Presentation
31 August 2019
thumbnail
Congress Session
Treatment strategies for atrial fibrillation in heart failure
17 May 2025
thumbnail
Congress Presentation
Morbidity and mortality parameters.
5 April 2022
thumbnail
Congress Presentation
1 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources